Investment Highlights for Sunshine Biopharma Inc.

Sunshine Biopharma Inc. (“Sunshine Biopharma” or “the Company”) is a revenue-generating pharmaceutical company focused on developing and marketing life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals.

Sunshine Biopharma’s proprietary therapeutic drug development program includes three product candidates: (1) Adva-27a, a small chemotherapy molecule for pancreatic cancer, (2) K1.1, a messenger RNA (mRNA) therapeutic for liver cancer, and (3) SBFM-PL4, a PLpro inhibitor for the treatment of COVID-19.

The Company’s proprietary pharmaceutical pipeline addresses large markets with significant unmet needs in oncology and antiviral indications, creating a diversified portfolio with a combined market potential of over $30 billion for the initial targeted indications.

- In preclinical trials, both Adva-27a and K1.1 have been effective against multidrug resistant (MDR) cancer cells in vitro, including pancreatic and breast cancer cells, among others.

- In February 2023, the Company signed a research agreement with the Jewish General Hospital in Montreal, Canada, to advance the development of Adva-27a through IND-enabling studies as well as negotiated terms for a subsequent Phase I clinical trial in patients with Stage 4 pancreatic cancer, which the Company expects to begin in 12 to 18 months (3Q 2025 to 1Q 2026).

- Sunshine Biopharma is conducting a proof-of-concept mice study to assess K1.1’s in vivo effect on liver cancer, with results expected by October/November 2023. Follow up toxicology studies are scheduled for 2Q 2024. Should these mouse studies prove successful, the Company plans to file an IND application to begin Phase 1 trials, potentially in 3Q 2024 or 4Q 2024.

- The Company plans to conduct explorative toxicity studies and proof-of-concept efficacy studies in hamsters for SBFM-PL4 (4Q 2023 to 2Q 2024), with additional ADME (absorption, distribution, metabolism, and excretion) in other species to begin by 2Q 2024. Following these studies, the Company expects to nominate a lead candidate formulation for an IND enabling study by 3Q 2024.

In addition to its proprietary drug development efforts, the Company also operates two wholly-owned subsidiaries: Nora Pharma Inc., a Canadian corporation with a portfolio of generic prescription drugs; and Sunshine Biopharma Canada Inc., a Canadian corporation, which sells OTC supplements.

On October 20, 2022, Sunshine Biopharma acquired Nora Pharma Inc., a generic pharmaceutical company that currently offers 50 generic prescription drugs in Canada with another 27 drugs scheduled to be launched in 2023 and 2024.

- According to the Company, the growth of its revenue-generating generic pharmaceutical business, through the operations of Nora Pharma, places Sunshine Biopharma on track to achieve profitability by FY 2025, with the generated cash flow expected to support and facilitate the development of its proprietary pharmaceutical pipeline. The Company believes that its revenue generating business, in conjunction with its focused proprietary drug development efforts, provide a low-risk model where the lengthy pharmaceutical development and approval process is supported by revenue generating activities.

In 2022 and YTD, Sunshine Biopharma completed four rounds of financing, generating total net proceeds of $47.7 million, which has enabled the Company to expand its proprietary drug development program and complete the acquisition of Nora Pharma. Furthermore, on May 16, 2023, the company completed a private placement for gross proceeds of $5 million (net proceeds of $4.1 million).

As of June 30, 2023, Sunshine Biopharma had a cash and cash equivalent position of $19.7 million.

* Updated on October 5, 2023.

Unlocking Visibility: Trusted Research by Wall Street Veterans